Nomura Instinet analyst Christopher Marai said Sarepta management called the complete response letter for golodirsen a surprise as the FDA recently suggested approval was on track. While the CRL delays his estimate for golodirsen approval and launch to the second half of 2020 from the end of 2019, Marai said there is no read-through to Exondys-51, casimersen or the company's gene therapy, which makes the weakness an attractive buying opportunity in his view. He is also not concerned about renal toxicity, as this is a well-known issue for the antisense oligonucleotides class and Marai said golodirsen's "PMO-chemistry appears to be among the safest ASOs in this regard." The analyst keeps a Buy rating and $230 price target on Sarepta shares.